A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro

British Journal of Cancer

Volumn 89, Issue 11, 2003, Pages 2140-2146

  Abou El Hassan, M A I ^a,b   Rabelink, M J W E ^b   Van Der Vijgh, W J F ^a   Bast, A ^c   Hoeben, R C ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adenovirus; Doxorubicin; Human catalase; MonoHER; MTT; Neonatal cardiac myocytes

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS ENCODING CATALASE; ADENOVIRUS VECTOR; CATALASE; DOXORUBICIN; FREE RADICAL; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; MONOHYDROXYETHYLRUTOSIDE; RUTOSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOTOXICITY; CATALASE GENE; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME RELEASE; GENE; GENE THERAPY; GENE TRANSFER; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; VIRAL GENE THERAPY; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CATALASE; CELL SURVIVAL; DOXORUBICIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEART DISEASES; HYDROXYETHYLRUTOSIDE; L-LACTATE DEHYDROGENASE; MYOCYTES, CARDIAC; RATS;

EID: 0347419308     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601430     Document Type: Article

References (44)

1. Abou El Hassan MAI, Heijn M, Rabelink MJ, van der Vijgh WJF, Bast A, Hoeben RC (2003) The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells. Cancer Gene Ther 10(4): 270-277
2. Aebi H (1984) Catalase in vitro. Methods Enzymol 105: 121-126
3. Bjorkman JA, Sutherland I, Gustafsson D, Sjoquist PO, Abrahamsson T (1991) Superoxide dismutase and catalase do not improve recovery of regional myocardial contractile function when given at the time of reperfusion after reversible ischemia anesthetized dogs. Basic Res Cardiol 86: 236-244
4. Chen Y, Saari JT, Kang YJ (1994) Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radical Biol Med 17: 529-536
5. Chen Y, Yu A, Saari JT, Kang YJ (1997) Repression of hypoxia- reoxygenation injury in the catalase-overexpressing heart of transgenic mice. PSEBM 216: 112-116
6. Chudej LL, Koke JR, Bittar N (1990) Evidence of transcytosis of exogenous superoxide dismutase and catalase from coronary capillaries in dog myocytes. Cytobios 63: 41-53
7. Cini Neri G, Neri B, Bandinelli M, Del Tacca M, Danesi R, Riccardi R (1991) Anthracycline cardiotoxicity: in vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat. Oncology 48: 327-333
8. Danel C, Erzurum SC, Prayssac P, Eissa NT, Crystal RG, Herve P, Baudet B, Mazmanian M, Lemarchand P (1998) Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNA protects against hyperoxia but not against ischemia-reperfusion lung injury. Hum Gene Ther 9: 1487-1496
9. Deshmukh DR, Mirochnitchenko O, Ghole VS, Agnese D, Shah PC, Reddell M, Brolin RE, Inouye M (1997) Intestinal ischemia and reperfusion injury in transgenic mice overexpressing copper-zinc superoxide dismutase. Am J Physiol 273: C1130-C1135
10. Doroshow JH, Locker JY, Meyers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65: 128-135
11. Erzurum SC, Lemarchand P, Rosenfeld MA, Yoo J, Crystal RG (1993) Protection of human endothelial cells from oxidant injury adenovirus-mediated transfer of the human catalase cDNA. Nucleic Acids Res 21: 1607-1612
12. Fallaux FJ, Bout A, Van der Velde I, Van den Wollenberg D, Hehir KM, Keegan J, Auger C, Cramer SJ, Van Ormondt H, Van der Eb AJVD, Hoeben RC (1998) New helper cells and matched early region 1-deleted adenoviral vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9: 1909-1917
13. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormond H, Hoeben RC, Van der Eb AJ (1996) Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7: 215-211
14. Goeptar AR, Groot EJ, Scheerens H, Commandeur JNM, Vermeulen NPE (1994) Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Cancer Res 54: 2411-2418
15. Goeptar AR, Te Koppele JM, Lamme EK, Pique JM, Vermeulen NPE (1993) Cytochrome P-450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 44: 1267-1277
16. Green MD, Alderton P, Gross J, Muggia FM, Speyer JL (1990) Evidence of the selective alteration of anthracyclines activity due to modulation by ICRF-187 (ADR-529). Pharmacol Ther 48: 61-69
17. Gross GJ, Farber NE, Hardman HF, Warltier DC (1986) Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am J Physiol 250: H372-H377
18. Ishikawa T, Akerboom TPM, Sies H (1986) Target Organ Toxicity. Boca Raton, FL: CRC Press, pp. 129-143
19. James Kang Y, Chen Y, Epstein PN (1996) Suppression of doxorubicin cardiotoxicity by overexpression of catalase in heart of transgenic mice. J Biol Chem 271: 12610-12610
20. Jeroudi MO, Triana FJ, Patel BS, Bolli R (1990) Effect of superoxide dismutase and catalase given separately on myocardial stunning. Am J Physiol 259: H889-H901
21. Kalyanaraman B, Sealy RC, Sinha BK (1984) An electron spin resonance study of the reduction of peroxides by anthracycline semiquinones. Biochem Biophys Acta 799: 270-275
22. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1990) Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47: 219-231
23. Kirshenbaum L, Singal PK (1993) Increase in endogenous antioxidant enzymes protects hearts against reperfusion injury. Am J Physiol 265: H484-H493
24. Koning J, Palmer P, Franks CR, Mulder DE, Speyer JL, Green MD, Hellmann K (1991) Cardioxane - ICRF-187. Towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev 18: 1-19
25. Li G, Chen Y, Saari JT, James Kang Y (1997) Catalase overexpressing transgenic mouse heart is resistant to ischemia reperfusion injury. Am J Physiol 273: H1090-H1095
26. Lin TJ, Liu GT, Pan Y, Liu Y, Xu GZ (1991) Protection by schisanhenol against adriamycin toxicity in rat heart mitochondria. Biochem Pharmacol 42: 1805-1810
27. 2-induced DNA damage and alter its site specificity. FEBES Lett 495(3): 187-190
28. Minotti G (1989) Adriamycin-dependent release of iron from microsomal membranes. Arch Biochem Biophys 268: 398-403
29. Moldeus P, Hogberg J, Orrenius S (1978) Isolation and use of liver cells. Methods Enzymol 52: 60-71
30. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63
31. Pietersen AM, Van der Eb MM, Rademaker HJ, Van den Wollenberg D, Tabelink MJ, Kuppen PJ, Van Dierendonck JH, Van Ormondt H, Masan D, Van de Velde CJ, Van der Eb AJ, Hoeben RC, Noterbon MH (1999) Specific tumor-cell killing with adenovirus vectors containing the appoptic gene. Gene Ther 6: 882-892
32. Przyklenk K, Kloner RA (1986) Superoxide dismutase plus catalase improve contractile function in the canine model of the 'stunned myocardium'. Circ Res 58: 148-156
33. 2, but also by potentiating the catalytic activity of ferrous ions. Toxicol Lett 2: 153-159
34. Takacs IE, Matkovics B, Varga SI, Homolay P, Feher G, Seres T (1992) Study of the myocardial antioxidant defense in various species. Pharmacol Res 25: 177-178
35. Thayer WS (1986) Role of catalase in metabolism of hydrogen peroxide by the perfused rat heart. FEBS Lett 202: 137-140
36. Van Acker FAA, Van Acker SABE, Kramer K, Haenen GRMM, Bast A, Van der Vijgh WJF (2000) MonoHER protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6(4): 1337-1341
37. Van Acker SABE, Boven E, Kuiper K, Van den Berg D, Grimbergen JA, Kramer A, Bast A, Van der Vijgh WJF (1997) Monohyroxyethylrutoside, a dose dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3: 1747-1754
38. Van Acker SABE, Van Balen GP, Van den Berg D, Bast A, Van der Vijgh WJF (1998) Influence of iron chelation on the antioxidant activity of flavonoids. Biochem Pharmacol 56(8): 935-943
39. Van Acker SABE, Van den Berg D, Tromp MNJL, Griffioen DH, Van Bennekom WP, Van der Vijgh WJF, Bast A (1996) Structural aspects of the antioxidant activity of flavonoids. Free Rad Biol Med 20: 331-342
40. Van Wamel JET, Ruwhof C, Van der Valk-Kokshoorn EJM, Schrier PI, Van der Laarse A (2000) Rapid gene transcription induced by stretch in cardiac myocytes and fibroblasts and their paracrine influence on stationary myocytes and fibroblasts. Eur J Physiol 439: 781-788
41. Villani F, Galimberti M, Poggi P, Rozza A, Lanza E, Favalli L, Scavini C. (1992) The effect of superoxide dismutase and catalase on the delayed toxicity of doxorubicin. Cardiologia 37: 709-711
42. Wagner H (1985) New plant phenolic of pharmaceutical interest. Annu Proc Phytochem Soc Eur 25: 409-425
43. Xing J, Yu Y, Rando TA (2002) The modulation of cellular susceptibility to oxidative stress: protective and destructive actions of Cu,Zn-superoxide dismutase. Neurobiol Dis 10(3): 234-246
44. Yu TW, Anderson D (1997) Reactive oxygen species-induced damage and its modification: a chemical investigation. Mutat Res 379(2): 201-210